Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

230.80USD
4:04pm EDT
Change (% chg)

$-6.99 (-2.94%)
Prev Close
$237.79
Open
$237.05
Day's High
$238.13
Day's Low
$229.72
Volume
994,966
Avg. Vol
655,170
52-wk High
$322.66
52-wk Low
$195.51

Select another date:

BRIEF-Allergan issues statement on Namenda XR patent litigation following announcement of ANDA approvals

* Company has settled with all other Namenda XR ANDA defendants, including Lupin Limited and Lupin Pharmaceuticals Inc

BRIEF-Allergan gets FDA approval of Natrelle Inspira cohesive breast implants

* Allergan announces FDA approval of natrelle inspira cohesive breast implants Source text for Eikon: Further company coverage:

BRIEF-Allergan and Adamas announce all four dosage strengths of NAMZARIC available throughout U.S.

* Co and Adamas Pharmaceuticals announce all four dosage strengths of NAMZARIC now available by prescription in pharmacies throughout U.S. Source text for Eikon: Further company coverage:

Allergan to buy Tobira in push for fatty liver disease drugs

Botox maker Allergan Plc, in its third acquisition this month, said it would pay up to $1.7 billion for Tobira Therapeutics Inc to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease closely linked to obesity.

UPDATE 3-Allergan to buy Tobira in push for fatty liver disease drugs

Sept 20 Botox maker Allergan Plc, in its third acquisition this month, said it would pay up to $1.7 billion for Tobira Therapeutics Inc to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease closely linked to obesity.

REFILE-DEALTALK-Allergan pays top dollar for 'stepping stones' from neurology to dermatology

Sept 20 Allergan Plc CEO Brent Saunders calls them "stepping stones" - small, bolt-on acquisitions, as opposed to the mega-deals common in the drug industry. And they're expected to boost dealmaking in sectors ranging from neurology to skin care.

Allergan pays top dollar for 'stepping stones' from neurology to dermatology

Allergan Plc CEO Brent Saunders calls them "stepping stones" - small, bolt-on acquisitions, as opposed to the mega-deals common in the drug industry. And they're expected to boost dealmaking in sectors ranging from neurology to skin care.

Allergan to buy Tobira in push for NASH treatments

Sept 20 Allergan Plc said it would buy Tobira Therapeutics Inc in a deal worth up to $1.7 billion, to gain access to its experimental therapies for a fatty liver disease called NASH.

Allergan must face antitrust class action over Alzheimer's drug

A proposed class action lawsuit brought by a health plan and a drug wholesaler accusing Allergan PLC of suppressing competition for its Alzheimer's drug Namenda can move forward, a federal judge ruled on Tuesday.

BRIEF-Allergan and Medicines360 announce launch of new Liletta 52 mg single-handed inserter

* Releasing intrauterine system) 52 mg single-handed inserter Source text for Eikon: Further company coverage:

Select another date: